Wenger Vieli advised Mobil in Time on the deal. Mobil in Time, a leader in mobile energy solutions and expert in water damage restoration, has completed...
You must be a Standard 1 Year member to access this content.
Wenger Vieli acted as Swiss legal advisor to NLS Pharmaceutics on the issuance. NLS Pharmaceutics has completed the registered direct offering and concurrent private placement transaction with...
You must be a Standard 1 Year member to access this content.
Wenger Vieli advised Verium on the deal. Zurich-based Verium AG has acquired a “significant minority stake” in Impact Acoustic AG. According to a statement from the...
You must be a Standard 1 Year member to access this content.
Wenger Vieli advised SWISS KRONO Group on the deal. SWISS KRONO Group, a globally renowned manufacturer of wood-based materials, completed the acquisition of Argolite. This acquisition...
You must be a Standard 1 Year member to access this content.
Wenger Vieli advised the lead investor Redalpine Opportunity Fund on the deal. Car subscription pioneer Carvolution has successfully closed a new financing round to further strengthen...
You must be a Standard 1 Year member to access this content.
Wenger Vieli advised NLS Pharmaceutics on the deal. NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for...
You must be a Standard 1 Year member to access this content.
Wenger Vieli advised the shareholders of MENU Technologies Ltd on the deal. MENU has become part of the NYSE listed PAR Technology Corp. group. The MENU...
You must be a Standard 1 Year member to access this content.
Schoenherr, Loloci & Partners, Pinsent Masons LLP and Wenger Vieli AG advised Kontron AG on the deal, Baker & McKenzie advised VINCI Energies. Kontron AG (formerly...
You must be a Standard 1 Year member to access this content.
Wenger Vieli advised NLS Pharmaceutics on the deal. NLS Pharmaceutics Ltd, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients...
You must be a Standard 1 Year member to access this content.
Wenger Vieli advised NLS Pharmaceutics on the deal. NLS Pharmaceutics Ltd, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients...
You must be a Standard 1 Year member to access this content.
Wenger Vieli advised Xeltis on the deal. Xeltis is a pioneering medtech firm developing medical devices enabling cardiovascular restoration. The Swiss/Dutch university spin-off landed a €15...
You must be a Standard 1 Year member to access this content.
Homburger advised Credit Suisse (Switzerland) Ltd. in connection with the financing of the acquisition. Bär & Karrer acted as legal advisor to the sellers in this...
You must be a Standard 1 Year member to access this content.
